GSK Plc (GSK)
50.84
+0.57
(+1.13%)
USD |
NYSE |
Aug 28, 16:00
50.84
0.00 (0.00%)
After-Hours: 20:00
GSK Cash from Operations (Quarterly) : 3.386B for June 30, 2026
Cash from Operations (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 3.386B |
| March 31, 2026 | 1.483B |
| December 31, 2025 | 2.744B |
| September 30, 2025 | 3.031B |
| June 30, 2025 | 2.464B |
| March 31, 2025 | 1.422B |
| December 31, 2024 | 2.835B |
| September 30, 2024 | 2.723B |
| June 30, 2024 | 1.111B |
| March 31, 2024 | 1.191B |
| December 31, 2023 | 3.619B |
| September 30, 2023 | 2.780B |
| June 30, 2023 | 1.339B |
| March 31, 2023 | 115.43M |
| December 31, 2022 | 1.750B |
| September 30, 2022 | 1.446B |
| June 30, 2022 | 1.585B |
| March 31, 2022 | 3.310B |
| December 31, 2021 | 4.703B |
| September 30, 2021 | 3.505B |
| June 30, 2021 | 1.349B |
| March 31, 2021 | 336.45M |
| December 31, 2020 | 4.627B |
| September 30, 2020 | 1.034B |
| June 30, 2020 | 2.988B |
| Date | Value |
|---|---|
| March 31, 2020 | 1.151B |
| December 31, 2019 | 3.872B |
| September 30, 2019 | 3.109B |
| June 30, 2019 | 1.396B |
| March 31, 2019 | 741.04M |
| December 31, 2018 | 5.118B |
| September 30, 2018 | 2.623B |
| June 30, 2018 | 1.540B |
| March 31, 2018 | 1.144B |
| December 31, 2017 | 3.261B |
| September 30, 2017 | 2.438B |
| June 30, 2017 | 940.07M |
| March 31, 2017 | 1.332B |
| December 31, 2016 | 3.483B |
| September 30, 2016 | 2.359B |
| June 30, 2016 | 1.448B |
| March 31, 2016 | 616.16M |
| December 31, 2015 | 1.852B |
| September 30, 2015 | 644.02M |
| June 30, 2015 | -52.48M |
| March 31, 2015 | 487.92M |
| December 31, 2014 | 3.159B |
| September 30, 2014 | 2.010B |
| June 30, 2014 | 919.98M |
| March 31, 2014 | 1.419B |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| AstraZeneca PLC | 3.420B |
| Eli Lilly & Co. | 10.69B |
| Merck & Co., Inc. | 5.37B |
| Pfizer Inc. | 835.00M |
| Sanofi | -- |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -1.176B |
| Cash from Financing (Quarterly) | -2.542B |
| Free Cash Flow | 6.621B |
| Free Cash Flow Per Share (Quarterly) | 1.236 |
| Free Cash Flow to Equity (Quarterly) | 3.434B |
| Free Cash Flow to Firm (Quarterly) | 2.892B |
| Free Cash Flow Yield | 6.38% |